TRIPLE-SWITCH (SWOG/CCTG-PR26): A randomized phase III clinical trial for the addition of docetaxel to androgen receptor pathway inhibitors in patients with metastatic castration sensitive prostate cancer (mCSPC) and suboptimal PSA response (NCT06592924).

Authors: Michael Ong, Alexandra Sokolova, Sebastien J. Hotte, Tanya B. Dorff, Kim N. Chi, Alexander William Wyatt, Amir Goldkorn, Michael Paul Kolinsky, Michael Donald Brundage, Akunne Ndika, Seth P. Lerner, Wendy R. Parulekar, Keyue Ding, Mariam Jafri

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps5129

Source: Full article

---

Abstract

TPS5129